NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Spero Therapeutics, Inc. Common Stock (SPRO) Stock Analysis

Spero Therapeutics, Inc. Common Stock (SPRO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SPRO

$1.17

−$0.05 (−4.10%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SPRO with… →

SPRO Key Statistics

As of Oct 21, 2026
Trading
Open
$1.21
Previous Close
$1.22
Day's Range
1.17–1.22
52-Week Range
1.08–3.08
Volume
265.71K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.50
Valuation
Market Cap
$68.13M
P/E Ratio
8.36
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.45
EPS (ttm)Profit attributable to each share over the last twelve months.
0.14
Financials (FY)
Revenue (FY)
$59.62M+117.62%
Net Income (FY)
$8.57M
Profit marginThe share of revenue left as profit after all costs and taxes.
15.71%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
58.23M
1-Year Return
−50.63%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
915.24K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SPRO closed at $1.17, −50.63% over 1 year.

Spero Therapeutics, Inc. Common Stock (SPRO) has a market capitalization of $68.13M.

In fiscal 2025, SPRO reported revenue of $59.62M.

SPRO Stock Return by Calendar Year

Spero Therapeutics, Inc. Common Stock (SPRO) return since Nov 2017: what $10,000 became

1 year
$10,000 $4,937
−50.63%
5 years
$10,000 $699
−93.01%
Since Nov 2017
$10,000 $1,017
−89.83%

If you had invested $10,000 in Spero Therapeutics, Inc. Common Stock (SPRO) at the close on November 2, 2017, the earliest close on record here, it would have been worth $1,017 at the close on October 21, 2026: −89.83% in total, −22.50% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−49.79%
2025+126.21%
2024−29.93%
2023−15.03%
2022−89.19%
2021−17.43%
2020+101.66%
2019+56.34%
2018−47.66%
2017 (partial year)+2.17%

As of October 21, 2026.

SPRO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$59.62M$8.57M14.4%
2024$27.40M−$68.57M−250.3%
2023$96.74M$22.81M23.6%
2022$48.58M−$46.42M−95.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$59.62M—$7.16M$8.57M14.4%
2024$27.40M—−$72.48M−$68.57M−250.3%
2023$96.74M—$26.79M$22.81M23.6%
2022$48.58M—−$30.57M−$46.42M−95.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SPRO Valuation vs Biotechnology Median

Median of 608 stocks
MetricSPROBiotechnology medianvs median
P/E8.3616.6050% below
P/S ratio1.4513.300.1x the median
Profit margin15.71%−38.31%54.0 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Spero Therapeutics, Inc. Common Stock (SPRO) at $68.13M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 25 employees.

SPRO last closed at $1.17 on October 21, 2026. That is −$0.05 (−4.10%) against the previous close. The 52-week range on file runs from $1.08 to $3.08. The latest close sits 8.33% above that 52-week low.

Financial Health

In fiscal 2025, Spero Therapeutics, Inc. Common Stock reported revenue of $59.62M. That is +117.62% against the prior fiscal year, when revenue was $27.40M. The same year closed with net income of $8.57M. Profit margin runs at 15.71%. That is 54 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to 0.14.

Across the 4 fiscal years on file, revenue moves from $48.58M in 2022 to $59.62M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 8.36. That is 49.64% below the Biotechnology median of 16.6. The price-to-sales ratio is 1.45. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.5. Daily returns over the trailing 9 years annualize to a volatility of 123.29%. The trailing one-year total return is −50.63%. Measured over 5 years, that is −41.27% a year compounded.

Growth & Income

No dividend is on file for SPRO.

So far in 2026 the total return is −49.79%. Across the complete calendar years on file, 2025 returned +126.21% and 2022 returned −89.19%. Of the 8 complete calendar years on file, 3 finished higher.

Peer Comparison

Spero Therapeutics, Inc. Common Stock (SPRO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Spero Therapeutics, Inc. Common Stock SPRO $68.13M 8.4
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Spero Therapeutics, Inc. Common Stock trades at a P/E of 8.4.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Spero Therapeutics, Inc. Common Stock

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Visit website →